Description: Lucibru ibrutinib 140 mg is the official generic of Imbruvica 140 mg. Lucibru ibrutinib 140 mg is a prescription medicine used to treat people with::: Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL):: Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion::Waldenström’s macroglobulinemia (WM):: Mantle cell lymphoma (MCL) who have received at least one prior treatment:: Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment::For MCL and MZL, Lucibru ibrutinib 140 mg is approved on response. Data are not yet available to show if Lucibru ibrutinib 140 mg improves survival or symptoms::It is not known if Lucibru ibrutinib 140 mg is safe and effective in children.
Ibrutinib: Ibrutinib is a targeted therapy used to treat mantle cell lymphoma, another type of lymphoma called Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia. How ibrutinib works: Ibrutinib is a type of targeted therapy drug called a tyrosine kinase inhibitor. It works by blocking (inhibiting) signals within cancer cells that make them grow and divide. This may help to stop or slow down the cancer growing.
There are no reviews yet.